原著
1) Imagawa T, Yokota S, Mori M, Miyamae T, Takei S, Imanaka H, Nerome Y, Iwata N, Murata T, Miyoshi M, Nishimoto N, Kishimoto T: Safety and efficacy of tocilizumab, an IL-6-receptor monoclonal antibody, in patients with polyarticular-course juvenile idiopathic arthritis. Mod Rheumatol. 2011;Jun 12 [Epub ahead of print]
2) Kawamura H, Nishi J, Imuta N, Tokuda K, Miyanohara H, Hashiguchi T, Zenmyo M, Yamamoto T, Ijiri K, Kawano Y, Komiya S. Quantitative analysis of biofilm formation of methicillin-resistant Staphylococcus aureus (MRSA) strains from patients with orthopaedic device-related infections. FEMS Immunol Med Microbiol. 2011;63(1):10-15
3) Koike T, Harigai M, Inokuma S, Ishiguro N, Ryu J, Takeuchi T, Takei S, Tanaka Y, Ito K, Yamanaka H.Postmarketing surveillance of tocilizumab for rheumatoid arthritis in Japan: interim analysis of 3881 patients. Ann Rheum Dis 2011;70(12): 2148-2151
4) Koike T, Harigai M, Naoki Ishiguro N, Inokuma S, Takei S, Takeuchi T, Yamanaka H, Tanaka Y. Safety and effectiveness of adalimumab in Japanese patients with rheumatoid arthritis: a report of the first 3,000 patients treated during postmarketing surveillance. Mod Rheumatol. 2011; Oct 13. [Epub ahead of print].
5) Lee S, Sanefuji M, Watanabe K, Uematsu A, Torisu H, Baba H, Kira R, Takada Y, Ishizaki Y, Toyoshima M, Aragaki F, Hata D, Hara T. Clinical and MRI characteristics of acute encephalopathy in congenital adrenal hyperplasia. J Neurol Sci. 2011;306(1-2):91-3
6) Matsumoto K, Shigemi A, Yaji K, Shimodozono Y, Takeda Y, Ikawa K, Morikawa N, Miyanohara H, Kawamura J, Orita M, Tokuda K, Nishi J, Yamada K: Reduction in the incidence of MRSA with use of alcohol-based hand rub solutions and gloves. J Infect Chemother 2011 Sep 6 [Epub ahead of print]
7) Miyahara E, Nishie M, Takumi S, Miyanohara H, Nishi J, Yoshiie K, Oda H, Takeuchi M, Komatsu M, Aoyama K, Horiuchi M, Takeuchi T. Environmental mutagens may be implicated in the emergence of drug-resistant microorganisms. FEMS Microbiol Lett. 2011;317(2):109-116
8) Mori M, Takei S, Imagawa T, Imanaka H, Nerome Y, Kurosawa R, Kawano Y, Yokota S, Sugiyama N, Yuasa H, Fletcher T, Wajdula JS. Etanercept in the treatment of disease-modifying anti-rheumatic drug(DMARD)-refractory polyarticular course juvenile idiopathic arthritis: experience from Japanese clinical trials. Mod rheumatol .2011;21(6):572-578
9) Mori M, Murata T, Takei S, Imagawa T, Yokota S. Acquisition of expanded indications for intravenous cyclophosphamide in the management of childhood rheumatic diseases in general. Mod rheumatol. 2011;21(5):449-457
10) Nishikawa T, Okamoto Y, Tanabe T, Shinkoda Y, Kodama Y, Kakihana Y, Goto M, Kawano Y. Acute respiratory distress syndrome as an initial presentation of hemophagocytic lymphohistiocytosis after induction therapy for acute myeloid leukemia. Pediatr Hematol Oncol. 2011:28(3):244-8
11) Nishikawa T, Izumo K, Miyahara E, Horiuchi M, Okamoto Y, Kawano Y, Takeuchi T. Benzene induces cytotoxicity without metabolic activation. J Occup Health. 2011;53(2):84-92.
12) Suematsu R, Ohta A, Matsuura E, Takahashi H, Fujii T, Horiuchi T, Minota S, Ishigatsubo Y, Ota T, Takei S, Soejima S, Inoue H, Koarada S, Tada Y, Nagasawa K. Therapeutic response of patients with adult Still’s disease to biologic agents: multicenter results in Japan. Mod Rheumatol. 2011 Dec 9 [Epub ahead of print]
13) Takei S. Systemic JIA as an autoinflammatory disease. Inflammation and Regeneration .2011; 31(1):52-65.
14) Ueno K, Nomura Y, Arata M, Maruyama S, Tanabe T, Eguchi T, Kawano Y. Development of Kawasaki syndrome in autoimmune neutropenia after treatment with granulocyte colony-stimulating factor. Pediatr Int. 2011;53(3):388-390
15) Yokota S, Imagawa T, Takei S, Murata T, Tomiita M, Itoh Y, Fujikawa S, Mori M.Guidance on using tocilizumab for juvenile idiopathic arthritis. Mod Rheumatol. 2011;21(6):563-571
16) Yoshinaga M, Kato Y, Nomura Y, Hazeki D, Yasuda T, Takahashi K, Higaki T, Tanaka Y, Wada A, Horigome H, Takahashi H, Ueno K, Suzuki H, Nagashima M. The QT intervals in infancy and time for infantile ECG screening for long QT syndrome. J Arrhythmia 2011:27;193-201
17) Kaida M, Morita-Hoshi Y, Soeda A, Wakeda T, Yamaki Y, Kojima Y, Ueno H, Kondo S, Morizane C, Ikeda M, Okusaka T, Takaue Y, Heike Y. Phase 1 trial of Wilms tumor 1 (WT1) peptide vaccine and gemcitabine combination therapy in patients with advanced pancreatic or biliary tract cancer. J Immunother. 2011;34(1):92-9